IN THE CLAIMS (37 CFR 1.121 Revised)

1. (previously presented) A compound of the formula



(I)

R^1 is hydrogen, (C_1-C_6)alkyl, unconjugated (C_3-C_6)alkenyl, $XC(=O)R^{13}$, benzyl or -CH_2CH_2-O-(C_1-C_4)alkyl;

R^2 and R^3 are selected, independently, from hydrogen, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, hydroxy, nitro, amino, halo, cyano, -SO_q(C_1-C_6)alkyl wherein q is zero, one or two, (C_1-C_6)alkylamino-, [(C_1-C_6)alkyl]$_2$amino-, -CO_2R^4, -$CONR^5R^6$, -$SO_2NR^7R^8$, -$C(=O)R^{13}$, -$XC(=O)R^{13}$, aryl-(C_0-C_3)alkyl- or aryl-(C_0-C_3)alkyl-O-, wherein said aryl is selected from phenyl and naphthyl, heteroaryl-(C_0-C_3)alkyl- or heteroaryl-(C_0-C_3)alkyl-O-, wherein said heteroaryl is selected from five to seven membered aromatic rings containing from one to four heteroatoms selected from oxygen, nitrogen and sulfur, and X^2(C_0-C_6)alkoxy-(C_0-C_6)alkyl-, wherein X^2 is absent or X^2 is (C_1-C_6)alkylamino- or [(C_1-C_6)alkyl]$_2$amino-, and wherein the (C_0-C_6)alkoxy-(C_0-C_6)alkyl- moiety of said X^2(C_0-C_6)alkoxy-(C_0-C_6)alkyl- contains at least one carbon atom, and wherein from one to three of the carbon atoms of said (C_0-C_6)alkoxy-(C_0-C_6)alkyl- moiety may optionally be replaced by an oxygen, nitrogen or sulfur atom, with the proviso that any two such heteroatoms must be separated by at least two carbon atoms, and wherein any of the alkyl moieties of said (C_0-C_6)alkoxy-(C_0-C_6)alkyl- may be optionally substituted with from two to seven fluorine atoms, and wherein one of the carbon atoms of each of the alkyl moieties of said aryl-(C_0-C_3)alkyl- and said heteroaryl-(C_0-C_3)alkyl- may optionally be replaced by an oxygen, nitrogen or sulfur atom, and wherein each of the foregoing aryl and heteroaryl groups may optionally be substituted with one or more substituents~~[, preferably from zero to two substituents,]~~ independently selected from (C_1-C_6)alkyl optionally substituted with from one to seven fluorine atoms, (C_1-C_6)alkoxy optionally substituted with from two to seven fluorine atoms, halo, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, hydroxy, nitro, cyano, amino, (C_1-C_6)alkylamino-, [(C_1-C_6) alkyl]$_2$amino-, -CO_2R^4, -$CONR^5R^6$, -$SO_2NR^7R^8$, -$C(=O)R^{13}$ and -$XC(=O)R^{13}$;

wherein each R^4, R^5, R^6, R^7, R^8 and R^{13} is selected, independently, from hydrogen and (C_1-C_6) alkyl, or R^5 and R^6, or R^7 and R^8 together with the nitrogen to which they are attached, form a pyrrolidine, piperidine, morpholine, azetidine, piperazine, N-(C_1-C_6)alkylpiperazine or thiomorpholine ring, or a thiomorpholine ring wherein the ring sulfur is replaced with a sulfoxide or sulfone; and

each X is, independently, (C_1-C_6)alkylene;

with the proviso that: (a) at least one of R^1, R^2 and R^3 must be ~~[the]~~ other than hydrogen, [and] (b) when R^2 and R^3 are both hydrogen, R^1 cannot be hydrogen, $(C_1$-$C_6)$alkyl, or unconjugated $(C_3$-$C_6)$alkenyl; ~~[and]~~ (c) both R^2 and R^3 cannot both simultaneously be nitro; and (d) when both R^2 and R^3 are amino and meta to a fused ring carbon atom then R^1 cannot be hydrogen, methyl or benzyl;
and pharmaceutically acceptable salts thereof.

2. - 3. (canceled)

4. (original) A compound according to claim 1, wherein one or both of R^2 and R^3 are $-C(=O)R^{13}$ wherein R^{13} is $(C_1$-$C_6)$alkyl.

5. (original) A compound according to claim 1, wherein one of R^2 and R^3 is $-COR^{13}$ wherein R^{13} is $(C_1$-$C_6)$alkyl or $(C_1$-$C_3)$alkyl optionally substituted with from one to seven fluorine atoms.

6. (original) A compound according to claim 1, wherein one of R^2 and R^3 is CF_3, fluoro, cyano or C_2F_5.

7. (currently amended) A pharmaceutical composition ~~[for use in reducing nicotine addiction or aiding in the cessation or lessening of tobacco use in a mammal, comprising an amount of a compound according to claim 1 that is effective in reducing nicotine addiction or aiding in the cessation or lessening of tobacco use]~~ comprising a pharmaceutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.

8. (original) A method for reducing nicotine addiction or aiding in the cessation or lessening of tobacco use in a mammal, comprising administering to said mammal an amount of a compound according to claim 1 that is effective in reducing nicotine addiction or aiding in the cessation or lessening of tobacco use.

9. (canceled)

10. (original) A method for treating a disorder or condition selected from inflammatory bowel disease, ulcerative colitis, pyoderma gangrenosum, Crohn's disease, irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrhythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supranuclear

palsy, chemical dependencies and addictions; dependencies on, or addictions to, nicotine, tobacco products, alcohol, benzodiazepines, barbiturates, opioids or cocaine; headache, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's Chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age related cognitive decline, epilepsy, petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome in a mammal, comprising administering to a mammal in need of such treatment an amount of a compound according to claim 1 that is effective in treating such disorder or condition.

11. - 14. (canceled)

15. (currently amended) A compound [~~according to claim 1~~] selected from the group consisting of 2-fluoro-N-(4-hydroxy-10-aza-tricyclo[6.3.1.$0^{2,7}$]dodeca-2(7),3,5-trien-5-yl)-benzamide; 1-(10-azatricyclo[6.3.1.$0^{2,7}$]dodeca-2(7),3,5-trien-4-yl)-1-ethanone;

and pharmaceutically acceptable salts thereof.

16. (currently amended) A compound [~~according to claim 3~~] selected from the group consisting of:

4-methyl-10-aza-tricyclo[6.3.1.$0^{2,7}$]dodeca-2(7),3,5-triene;
4-nitro-10-azatricyclo[6.3.1.$0^{2,7}$]dodeca-2(7),3,5-triene;
4-amino-10-azatricyclo[6.3.1.$0^{2,7}$]dodeca-2(7),3,5-triene;
N^1-[10-azatricyclo[6.3.1.$0^{2,7}$]dodeca-2(7),3,5-trien-4-yl]acetamide;
4,5-difluoro-10-aza-tricyclo[6.3.1.$0^{2,7}$]dodeca-2(7),3,5-triene;
4-chloro-10-azatricyclo[6.3.1.$0^{2,7}$]dodeca-2(7),3,5-triene;
3-(10-azatricyclo[6.3.1.$0^{2,7}$]dodeca-2(7),3,5-trien-4-yl)-5-methyl-1,2,4-oxadiazole;
10-azatricyclo[6.3.1.$0^{2,7}$]dodeca-2(7),3,5-trien-4-ol;
4,5-dichloro-10-azatricyclo[6.3.1.$0^{2,7}$]dodeca-2(7),3,5-triene;
N^4,N^4-dimethyl-10-azatricyclo[6.3.1.$0^{2,7}$]dodeca-2(7),3,5-triene-4-sulfonamide;
4-(1-pyrrolidinylsulfonyl)-10-azatricyclo[6.3.1.$0^{2,7}$]dodeca-2(7),3,5-triene;
5-fluoro-10-aza-tricyclo[6.3.1.$0^{2,7}$]dodeca-2(7),3,5-triene-4-carbonitrile;
4-ethynyl-5-fluoro-10-aza-tricyclo[6.3.1.$0^{2,7}$]dodeca-2(7),3,5-triene;
5-ethynyl-10-aza-tricyclo[6.3.1.$0^{2,7}$]dodeca-2(7),3,5-triene-4-carbonitrile;
5-chloro-10-aza-tricyclo[6.3.1.$0^{2,7}$]dodeca-2(7),3,5-triene-4-carbonitrile;
4-ethynyl-5-chloro-10-aza-tricyclo[6.3.1.$0^{2,7}$]dodeca-2(7),3,5-triene;
4-fluoro-5-trifluoromethyl-10-aza-tricyclo[6.3.1.$0^{2,7}$]dodeca-2(7),3,5-triene;
4-chloro-5-trifluoromethyl-10-aza-tricyclo[6.3.1.$0^{2,7}$]dodeca-2(7),3,5-triene;

5-trifluoromethyl-10-aza-tricyclo[6.3.1.$0^{2,7}$]dodeca-2(7),3,5-triene-4-carbonitrile;
4-ethynyl-5-trifluoromethyl-10-aza-tricyclo[6.3.1.$0^{2,7}$]dodeca-2(7),3,5-triene;
4,5-bistrifluoromethyl-10-aza-tricyclo[6.3.1.$0^{2,7}$]dodeca-2(7),3,5-triene;
and pharmaceutically acceptable salts thereof.

17. (previously presented) A compound according to claim 6 selected from the group consisting of:
3-trifluoromethyl-10-aza-tricyclo[6.3.1.$0^{2,7}$]dodeca-2(7),3,5-triene;
4-trifluoromethyl-10-aza-tricyclo[6.3.1.$0^{2,7}$]dodeca-2(7),3,5-triene;
3-fluoro-10-aza-tricyclo[6.3.1.$0^{2,7}$]dodeca-2(7),3,5-triene;
10-azatricyclo[6.3.1.$0^{2,7}$]dodeca-2(7),3,5-trien-4-yl cyanide;
4-fluoro-10-aza-tricyclo[6.3.1.$0^{2,7}$]dodeca-2(7),3,5-triene;
and pharmaceutically acceptable salts thereof.

18. (previously presented) A compound according to claim 1 that is:
4-nitro-10-azatricyclo[6.3.1.$0^{2,7}$]dodeca-2(7),3,5-triene; or a pharmaceutically acceptable salt thereof.

19. (previously presented) A compound according to claim 1 that is:
4,5-dichloro-10-azatricyclo[6.3.1.$0^{2,7}$]dodeca-2(7),3,5-triene; or a pharmaceutically acceptable salt thereof.

20. (previously presented) A compound according to claim 1 that is:
3-trifluoromethyl-10-aza-tricyclo[6.3.1.$0^{2,7}$]dodeca-2(7),3,5-triene; or a pharmaceutically acceptable salt thereof.

21. (previously presented) A compound according to claim 1 that is:
3-fluoro-10-aza-tricyclo[6.3.1.$0^{2,7}$]dodeca-2(7),3,5-triene; or a pharmaceutically acceptable salt thereof.

22. (previously presented) A compound according to claim 1 that is:
4-ethynyl-5-fluoro-10-aza-tricyclo[6.3.1.$0^{2,7}$]dodeca-2(7),3,5-triene; or a pharmaceutically acceptable salt thereof.

23. (previously presented) A compound according to claim 1 that is:
4-fluoro-5-trifluoromethyl-10-aza-tricyclo[6.3.1.$0^{2,7}$]dodeca-2(7),3,5-triene; or a pharmaceutically acceptable salt thereof.